Rostec Began Nationwide Supplies Of Tetravalent Influenza Vaccine

Health 2023
Rostec Began Nationwide Supplies Of Tetravalent Influenza Vaccine
Rostec Began Nationwide Supplies Of Tetravalent Influenza Vaccine

Video: Rostec Began Nationwide Supplies Of Tetravalent Influenza Vaccine

Отличия серверных жестких дисков от десктопных
Video: Why Doesn’t the Flu Vaccine Always Work? 2023, February
Anonim

Photo: National Immunobiological Company

Image
Image

The National Immunobiological Company of the State Corporation Rostec has begun centralized supplies of the Ultrix Quadri quadrivalent vaccine to the Russian regions as part of meeting the needs of the National Calendar of Preventive Vaccinations. By the end of November, 7.5 million doses of the vaccine will be delivered to the constituent entities of the Russian Federation, in accordance with the terms of state contracts concluded by the company with the Russian Ministry of Health.

"Ultrix Quadri" provides active immunization against four strains of the influenza virus - two subtypes of the type virus and two subtypes of the B virus. flu prevention.

“In accordance with the state program for the gradual transition to the prevention of influenza with quadrivalent vaccines, in 2019 we began to produce the modern quadrivalent vaccine Ultrix Quadri in a full cycle. This year, the volume of supply of this vaccine for immunizing the population within the framework of the National Calendar of Preventive Vaccinations has been increased by 40% compared to the last epidemic season,”said Andrei Zagorsky, Director General of Natsimbio.

In addition to supplying the Ultrix Quadri quadrilent vaccine, Natsimbio has also been supplying trivalent influenza vaccines for children and adults since August. To date, the company has donated over 60 million doses of domestic vaccines to immunize the population.

Since 2019, the Ultrix Quadri vaccine has been produced using a full cycle technology in compliance with GMP standards at the FORT plant in the Ryazan region (part of Natsimbio and the investment company Marathon Group). This year, at least 10 million doses of the vaccine will be produced on the Russian and foreign markets.

The drug is safe, significantly reduces the risk of influenza and contributes to the formation of strong immunity. The vaccine undergoes serial quality control in independent laboratories, and its delivery is carried out through the "cold chain" system with the use of continuous temperature monitoring. Vaccine development began in 2017, at the same time WHO recommended quadrivalent vaccines for use worldwide as a priority.

Popular by topic